AOD-9604 vs Liraglutide
Both AOD-9604 and Liraglutide are used for weight-loss. Here's how their evidence, dosing, and regulatory status actually compare.
AOD-9604
Evidence C+Anti-Obesity Drug 9604
A modified fragment of human growth hormone (hGH 176-191) that stimulates fat breakdown without the growth-promoting or diabetogenic effects of full HGH.
View full AOD-9604 profile →Liraglutide
Evidence A+Liraglutide (Saxenda / Victoza)
The original once-daily GLP-1 receptor agonist. Lower weight-loss magnitude than semaglutide but a longer real-world track record across diabetes and obesity.
View full Liraglutide profile →Side-by-Side
| Attribute | AOD-9604 | Liraglutide |
|---|---|---|
| Evidence Grade | C+ | A+ |
| FDA Status | Not FDA-approved — Category 1 (compounding allowed) | FDA-approved for weight management (Saxenda) and type 2 diabetes (Victoza) |
| Typical Dose | 250–500 mcg daily (subcutaneous) | 0.6–3.0 mg daily (subcutaneous) |
| Clinics Indexed | 134 | 540 |
| Categories | weight-loss, fat-loss | weight-loss, metabolic |
Key reported benefits — AOD-9604
- ✓Fat metabolism
- ✓No HGH side effects
- ✓Cartilage repair potential
Key reported benefits — Liraglutide
- ✓Weight loss
- ✓Appetite suppression
- ✓Glycemic control
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.